Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
May 07, 2019
TickeronGET DAILY SIGNALS
Regeneron (REGN, $324.94) misses Q1 earnings and revenue estimates

Regeneron (REGN, $324.94) misses Q1 earnings and revenue estimates

Regeneron Pharmaceuticals’ first-quarter earnings came in lower  than what analysts expected.

Regeneron raked in adjusted earnings of $4.45 per share, missing Wall Street's expectation of $5.52. Revenue of $1.71 billion also was lower than analysts' $1.76 billion expectations. 

CEO Leonard Schleifer emphasized that the company is optimistic about the potential of its  product Dupixent, which is now FDA-approved in atopic dermatitis and asthma in both adults and adolescents and is currently under Priority Review by the FDA for chronic rhinosinusitis with nasal polyps.

Related Ticker: REGN

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


REGN in upward trend: 10-day moving average moved above 50-day moving average on October 26, 2026

The 10-day moving average for REGN crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on REGN as a result. In 58 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.

The Moving Average Convergence Divergence (MACD) for REGN just turned positive on October 14, 2026. Looking at past instances where REGN's MACD turned positive, the stock continued to rise in 35 of 49 cases over the following month. The odds of a continued upward trend are 71%.

REGN moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in 203 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

The Aroon Indicator entered an Uptrend today. In 186 of 264 cases where REGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.

Bearish Trend Analysis

The 10-day RSI Indicator for REGN moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 15 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 37%.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.

REGN broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 3 (best 1 - 100 worst), indicating outstanding price growth. REGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 62 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.936) is normal, around the industry mean (3.498). P/E Ratio (21.599) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (1.238) is also within normal values, averaging (9.059). Dividend Yield (0.004) settles around the average of (130.981) among similar stocks. P/S Ratio (5.339) is also within normal values, averaging (440.869).

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -1%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was -17%. PEPG experienced the highest price growth at 117%, while KPTI experienced the biggest fall at -71%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -49%. For the same stocks of the Industry, the average monthly volume growth was -24% and the average quarterly volume growth was -33%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of medicines for the treatment of serious medical conditions

Industry Biotechnology

Industry
Biotechnology
Address
777 Old Saw Mill River Road
Phone
+1 914 847-7000
Employees
15410
Web
https://www.regeneron.com
Interact to see
Advertisement
AMD fell -5.03% to $555.85 in regular-session trading Friday, down -$29.45 from Thursday's close of $585.30, as of 9:42 a.m. ET shortly after the opening bell. No verified company-specific news or fundamental catalyst found: the decline tracks a broad semiconductor pullback and is consistent with profit-taking after a +44.7% rebound from the Nov. 5 close of $404.40, with the stock's typical daily swing running at 3.6%.
BZ dropped sharply, sliding from a $16.72 prior close to $13.48 (-19.38%), with the decline beginning in premarket and deepening into the early regular session. No verified company-specific news or fundamental catalyst was issued; the fall tracked a broad China ADR selloff (the Nasdaq Golden Dragon index slid more than 2%), but that alone is too small to explain a ~20% drop — the stock's Hong Kong listing fell only -2.6%.
NBIS fell from $154.69 to $129.12, down -16.53%, with the decline starting in premarket trading and continuing through the regular session. The drop followed Q3 results: revenue of $980.8M (+571% YoY) beat estimates, but management cut 2026 revenue guidance to the low end of its range on third-party capacity delays and raised 2026 capex to roughly $27B, reviving financing and execution fears.
The $1 target in this article is not an analyst price target; it is the $1.00 Nasdaq minimum bid price requirement, the level Cenntro itself has publicly targeted through a 1-for-60 reverse stock split. Cenntro trades near $0.12 per share, meaning reaching $1 would require an increase of roughly 730%—an exceptionally large move.
The central target of $21 is the arithmetic mean of three recently attributable analyst price targets on RUM — $25 (Lake Street), $15 (Texas Capital), and $22 (Maxim Group) — which average roughly $20.67. With shares trading near $5.90 after a post-earnings surge, reaching $21 would require a gain of roughly 256%, a very large move.